IBIO Stock — iBio Inc.: Cash, EV, Pipeline

What they do

iBio, Inc. (also referred to as “we”, “us”, “our”, “iBio”, or the “Company”) is a clinical-stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases.

Source: 10-K FY2026 via SEC EDGAR

Share price

$0.74

Market cap

$47.5M

Cash

$88.0M

Enterprise value

-$40.5M

Balance sheet

Cash	$88.0M
Debt	$0.0M
Net cash	$88.0M
Enterprise value	-$40.5M
Basic shares	55.7M shares
Fully diluted shares	190.1M shares
Fully diluted market cap	$140.7M
Cash per share	$1.58
Quarterly burn	$6.2M
Cash runway	14.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

55.7M

Pre-funded warrants

95.8M

Options

2.8M

RSUs

0.0M

Warrants

35.8M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

190.1M

Cap table as of 2026-06-30.

Price history

Loading IBIO daily closes…

Loading price history…

Next catalyst

IBIO-600 · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	IBIO-600 Phase 1 first interim data · NCT07487376	Phase 1	Not disclosed	Q1 2027
Jun 12 - Jul 24 in 7 mo	IBIO-600	Phase 1	Overweight , Obesity	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IBIO-600

Preclinical · Active Modality: antibody

Target myostatin

Indications

Obesity (Preclinical)

Catalysts

— second quarter 2026

Status note Next-generation antibody therapeutic for obesity; company anticipated Phase 1a entry in Australia in the second quarter of 2026. Target not explicitly stated in the excerpts.

IBIO-610

Preclinical · Active Modality: antibody

Target Activin E

Partnerships AstralBio, Inc.: exclusive worldwide license agreement related to Activin E (April 21, 2025); AstralBio licensed its Activin E rights to the Company

Indications

Obesity (Preclinical)

Status note Preclinical long-acting Activin E-inhibiting antibody for obesity.

IBIO-101

Stage not disclosed · Active Modality: antibody

Partnerships RubrYc assets acquired September 16, 2022 (asset purchase agreement)

Indications

Oncology (Stage not disclosed)

Status note Oncology program acquired from RubrYc. Initiating in Q2 FY2026, the Company actively marketed and identified potential partners for IBIO-101 and the other oncology programs; oncology is de-prioritized relative to obesity. No stage disclosed.

Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IBIO-600
Lead indication	Overweight , Obesity
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07487376	Phase 1	Recruiting	Sponsor	IBIO	—	Overweight , Obesity	Q1 2027 Est. Feb 14, 2027 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for iBio, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Cormorant Asset Management	3,570,000	+3,570,000	0.32%	2026-08-14
Frazier Life Sciences	1,953,467	no change	0.07%	2026-08-14
Ikarian Capital	957,062	no change	0.27%	2026-08-14
Ally Bridge Group	390,147	+390,147	0.88%	2026-08-14
ADAR1 Capital Management	375,531	-94,347	0.03%	2026-08-14
DAFNA Capital	170,053	-23,585	0.06%	2026-08-14
Logos Global Management	0	-1,300,000	0.00%	2026-08-14
EcoR1 Capital	0	-1,583,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

IBIO — iBio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IBIO — iBio Inc.